Advertisement

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

John C. Byrd, Richard R. Furman, Steven E. Coutre, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James and Susan O'Brien

Article Information

Citation 
vol. 125 no. 16 2497-2506
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted October 31, 2014
  • Accepted February 3, 2015
  • Published online April 16, 2015.

Article Versions


Contributors 
  • John C. Byrd, 1The Ohio State University, Columbus, OH;
  • Richard R. Furman, 2Weill Cornell Medical College, New York, NY;
  • Steven E. Coutre, 3Stanford Cancer Center and Stanford University School of Medicine, Stanford, CA;
  • Jan A. Burger, 4The University of Texas MD Anderson Cancer Center, Houston, TX; and
  • Kristie A. Blum, 1The Ohio State University, Columbus, OH;
  • Morton Coleman, 2Weill Cornell Medical College, New York, NY;
  • William G. Wierda, 4The University of Texas MD Anderson Cancer Center, Houston, TX; and
  • Jeffrey A. Jones, 1The Ohio State University, Columbus, OH;
  • Weiqiang Zhao, 1The Ohio State University, Columbus, OH;
  • Nyla A. Heerema, 1The Ohio State University, Columbus, OH;
  • Amy J. Johnson, 1The Ohio State University, Columbus, OH;
  • Yun Shaw, 5Pharmacyclics, Inc, Sunnyvale, CA
  • Elizabeth Bilotti, 5Pharmacyclics, Inc, Sunnyvale, CA
  • Cathy Zhou, 5Pharmacyclics, Inc, Sunnyvale, CA
  • Danelle F. James, 5Pharmacyclics, Inc, Sunnyvale, CA
  • Susan O'Brien, 4The University of Texas MD Anderson Cancer Center, Houston, TX; and

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output